- Enrollment in sebetralstat KONFIDENT phase 3 trial passes 50% milestone; data remains H2 2023– - Sebetralstat phase 2 data published in The Lancet – - Company funded into 2025 – CAMBRIDGE, Mass. & SALISBURY, United Kingdom --(BUSINESS WIRE)--Mar. 9, 2023-- KalVista Pharmaceuticals, Inc ....

– Orally disintegrating tablet formulation shows similar pharmacokinetics to current film-coated tablets supporting lifecycle extension in US and EU - – Real-word evidence and patient survey data demonstrate treatment burden associated with the administration of injectable on-demand treatments in...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 16, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of...

- Phase 3 KONFIDENT clinical trial passes 50% enrollment milestone - - Topline data still expected in H2 2023 - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 14, 2023-- KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 10, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that results from...

– Oral sebetralstat regimen for short-term prophylaxis to be evaluated in KONFIDENT-S – – Positive phase 1 sebetralstat data supports KONFIDENT trial expansion to Japan   – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 7, 2023-- KalVista Pharmaceuticals, Inc....

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 3, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 2, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of...

- Expanded role to lead business and commercial growth – - Follows $58 million financing in December 2022 led by top-tier syndicate – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 5, 2023-- KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 4, 2023-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 1,000 shares of...